S.F. Holding(002352.SZ) achieved a total revenue of 22.981 billion yuan in August in its express logistics, supply chain, and international business.
Shunfeng Holding Group (002352.SZ) disclosed the business operation brief of express logistics in August 2024, in the year 2024...
S.F. Holding (002352.SZ) disclosed the business operating report of its express logistics business in August 2024. In August 2024, the company's express logistics business operating income was 16.346 billion yuan, an increase of 8.58% year-on-year; business volume was 1.043 billion tickets, an increase of 14.62% year-on-year; and the average income per ticket was 15.67 yuan, a decrease of 5.26% year-on-year. The supply chain and international business operating income was 6.635 billion yuan, an increase of 27.16% year-on-year.
The total income of the company's express logistics business, supply chain, and international business in August 2024 was 22.981 billion yuan, an increase of 13.36% year-on-year. Benefiting from the increase in international shipping fees and stable cargo volume, as well as the increase in international air freight demand, the company's international freight and agency business income achieved a high year-on-year growth. At the same time, the company continues to deepen business integration and continuously explore the supply chain and international market.
Related Articles

"Galaxy Macau" announces a three-year strategic partnership with DAMAI ENT (01060) and Macau Pass to jointly promote the upgrade of the Macau cultural and entertainment industry.

HK Stock Market Move | REMEGEN (09995) rose more than 5%, and the results of the Phase III clinical study of Taetexinib for the treatment of systemic lupus erythematosus in China were published in NEJM.

Breakthrough progress! Luopu Biology (02157) has completed the enrollment of the first patient in Phase II clinical trial for liver cell carcinoma.
"Galaxy Macau" announces a three-year strategic partnership with DAMAI ENT (01060) and Macau Pass to jointly promote the upgrade of the Macau cultural and entertainment industry.

HK Stock Market Move | REMEGEN (09995) rose more than 5%, and the results of the Phase III clinical study of Taetexinib for the treatment of systemic lupus erythematosus in China were published in NEJM.

Breakthrough progress! Luopu Biology (02157) has completed the enrollment of the first patient in Phase II clinical trial for liver cell carcinoma.
